Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q2 EPS of ($0.12), $0.05 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $9.07 million versus the consensus estimate of $8.8 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.